PHARMOBEDIENT Company Profile

What is the competitive landscape for PHARMOBEDIENT

PHARMOBEDIENT has three hundred and twenty-one approved drugs.

There is one US patent protecting PHARMOBEDIENT drugs. There is one tentative approval on PHARMOBEDIENT drugs.

There are twenty-one patent family members on PHARMOBEDIENT drugs in sixteen countries and six hundred and eighty-one supplementary protection certificates in nineteen countries.

Summary for PHARMOBEDIENT

International Patents:	21
US Patents:	1
Tradenames:	248
Ingredients:	236
NDAs:	321

Drugs and US Patents for PHARMOBEDIENT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	FOSPHENYTOIN SODIUM	fosphenytoin sodium	INJECTABLE;INJECTION	078736-001	Jun 8, 2010		DISCN	No	No
Pharmobedient	RISEDRONATE SODIUM	risedronate sodium	TABLET;ORAL	200477-004	Jun 10, 2014		DISCN	No	No
Pharmobedient	ZOLPIDEM TARTRATE	zolpidem tartrate	TABLET;SUBLINGUAL	202657-001	Aug 8, 2016		DISCN	No	No
Pharmobedient	CLINDAMYCIN HYDROCHLORIDE	clindamycin hydrochloride	CAPSULE;ORAL	091225-001	May 31, 2011		DISCN	No	No
Pharmobedient	ZONISAMIDE	zonisamide	CAPSULE;ORAL	077647-003	Dec 22, 2005		DISCN	No	No
Pharmobedient	TOBRAMYCIN	tobramycin	SOLUTION;INHALATION	209554-001	Oct 13, 2017		DISCN	No	No

Expired US Patents for PHARMOBEDIENT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pharmobedient	ACCUNEB	albuterol sulfate	SOLUTION;INHALATION	020949-002	Apr 30, 2001	6,702,997
Pharmobedient	OLUX E	clobetasol propionate	AEROSOL, FOAM;TOPICAL	022013-001	Jan 12, 2007	6,730,288
Pharmobedient	ENLON-PLUS	atropine sulfate; edrophonium chloride	INJECTABLE;INJECTION	019678-001	Nov 6, 1991	4,952,586
Pharmobedient	LUXIQ	betamethasone valerate	AEROSOL, FOAM;TOPICAL	020934-001	Feb 28, 1999	6,126,920
Pharmobedient	DEMADEX	torsemide	TABLET;ORAL	020136-004	Aug 23, 1993	4,822,807
Pharmobedient	DEMADEX	torsemide	TABLET;ORAL	020136-004	Aug 23, 1993	RE30633

Paragraph IV (Patent) Challenges for PHARMOBEDIENT drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Foam	0.12%		2007-08-10
	Inhalation Solution	0.021% and 0.042%		2005-10-19
	Topical Foam	0.05%		2005-06-27

International Patents for PHARMOBEDIENT Drugs

Country	Patent Number	Estimated Expiration
Taiwan	I397427
Poland	1796636
Argentina	051197
Hong Kong	1110198
Russian Federation	2007111706
Russian Federation	2381023

Supplementary Protection Certificates for PHARMOBEDIENT Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0459136	C970044	Netherlands		PRODUCT NAME: CANDESARTAN, DESGENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF VAN DE 1-(CYCLOHEXYLOXYCARBONYLOXY) ETHYLESTE R, IN HET BIJZONDER CILEXETILI CANDESARTANAS, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: RVG 21703 - RVG 21706 19971013; FIRST REGISTRATION: GB PL 15661/0001 - PL 15661/0004 19970429
2673237	LUC00111	Luxembourg		PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; AUTHORISATION NUMBER AND DATE: EU/1/17/1173 20180326
2924034	PA2019507,C2924034	Lithuania		PRODUCT NAME: DORAVIRINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, DERINYJE SU LAMIVUDINU IR TENOFOVIRO DIZOPROKSILIO FUMARATU; REGISTRATION NO/DATE: EU/1/18/1333 20181122
0247633	C970034	Netherlands		PRODUCT NAME: ATORVASTATINUM,DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF VAN HET INWENDIGE DELTA-LACTON, IN HET BIJZONDER ATORVASTATINUM CALCICUM TRIHYDRICUM; NAT. REGISTRATION NO/DATE: RVG 21081 - RVG 21083 19970421; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
0186405	SPC/GB00/021	United Kingdom		PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
1044189	SPC/GB08/034	United Kingdom		PRODUCT NAME: VARENICLINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE TARTRATE SALT; REGISTRATION NO/DATE: EU/1/06/360/001 - 010 20060928

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Pharm Assoc
• Pharm Res Assoc
• Pharm Spec
• Pharm Ventures
• Pharma Serve Ny
• Pharmaand

PHARMOBEDIENT Competitive Landscape Analysis: Market Position, IP Strength, and Strategic Moves

Last updated: July 10, 2026

Executive summary: PHARMOBEDIENT is not identifiable as a specific FDA-approved drug product, biologic, or active ingredient from the information provided. Without a determinable drug identity (active ingredient, brand name, sponsor/MAH, dosage form, and FDA application), no accurate Orange Book status, patent estate, exclusivity windows, Paragraph IV risk, or litigation can be mapped to support a competitive landscape assessment.

What is PHARMOBEDIENT in the US market, and who manufactures it?

Answer: Not determined from the provided input.

What active ingredient does PHARMOBEDIENT contain?

Not determined.

Is PHARMOBEDIENT an NDA, ANDA, BLA, or OTC product?

Not determined.

What dosage forms and strengths exist?

Not determined.

What is the Orange Book status of PHARMOBEDIENT?

Answer: Not determined.

Are there FDA-listed patents for PHARMOBEDIENT?

Not determined.

Which patent types appear (drug substance, drug product, method of use)?

Not determined.

What are the listed expiration dates and exclusivity end dates?

Not determined.

What patents protect PHARMOBEDIENT, and how strong is the patent estate?

Answer: Not determined.

How many patents cover PHARMOBEDIENT across composition, formulation, and use?

Not determined.

Who are the assignees of the key patents?

Not determined.

What jurisdiction coverage exists (US only vs. global families)?

Not determined.

When does PHARMOBEDIENT lose exclusivity or patent protection?

Answer: Not determined.

What are the expected earliest US launch dates for generics?

Not determined.

What exclusivity periods apply (NCE, 5-year, 3-year, pediatric, orphan)?

Not determined.

What is the timing risk for at-risk launches?

Not determined.

What generic entry risks exist for PHARMOBEDIENT, including Paragraph IV?

Answer: Not determined.

Have any Paragraph IV challenges been filed?

Not determined.

Which generic companies are potential challengers?

Not determined.

What settlement or consent judgments affect entry timing?

Not determined.

What formulations are protected by PHARMOBEDIENT patents?

Answer: Not determined.

Are there protected technologies (extended-release, tamper-resistant, particulate, co-crystal)?

Not determined.

Are manufacturing processes patented (drying, granulation, sterilization, aseptic fill-finish)?

Not determined.

What method-of-use patents protect PHARMOBEDIENT?

Answer: Not determined.

Are there line-extension indications (new dosing, patient subsets, combination regimens)?

Not determined.

What claim scopes are likely to be infringed by labeled use?

Not determined.

Which companies are challenging PHARMOBEDIENT, and what does litigation show?

Answer: Not determined.

What patent litigation affects PHARMOBEDIENT?

Not determined.

What are the key court dates and outcomes?

Not determined.

What patents were asserted, and against which generic applicants?

Not determined.

How does PHARMOBEDIENT compare with competing brands and generics?

Answer: Not determined.

What are the therapeutic alternatives and substitution patterns?

Not determined.

How do pricing and access differ among competitors?

Not determined.

Are there competitive differentiation levers (onset, safety, adherence, device delivery)?

Not determined.

What FDA regulatory pathway does PHARMOBEDIENT use, and how does it affect competitive entry?

Answer: Not determined.

Is it approved via 505(b)(1), 505(b)(2), or 505(j)?

Not determined.

Is there REMS, risk management, or restricted distribution?

Not determined.

Are there biosimilar-like risks (if PHARMOBEDIENT is a biologic)?

Not determined.

Commercial strategy: where is PHARMOBEDIENT exposed to revenue erosion?

Answer: Not determined.

What is the maturity of the market (new launch vs. entrenched)?

Not determined.

What are the most likely first-wave generic or switch drivers?

Not determined.

What payer pressures exist (PBM position, formulary status, prior auth)?

Not determined.

Key Takeaways

• PHARMOBEDIENT cannot be connected to a specific US-regulated product, active ingredient, or FDA application based on the provided input.
• No defensible analysis of Orange Book listings, exclusivity timelines, patent scope, Paragraph IV risk, litigation, or competitive substitution can be produced without a determinable drug identity.

FAQs

1. How do I find the correct Orange Book record for a brand when the manufacturer is unclear?
2. What is the typical patent coverage map for a US small-molecule brand (drug substance, drug product, method-of-use)?
3. How does pediatric exclusivity interact with listed Orange Book patents for launch timing?
4. What claim elements most often drive non-infringement or design-around arguments in Paragraph IV cases?
5. What data points best predict generic erosion risk for an established brand (patent count, expirations, exclusivity end dates, litigation posture)?

References

1. Not provided.